GoLiver Therapeutics is the winner of the France 2030 “innovation in Biotherapies and Bioproduction” call for its GOCLINICALS project, dedicated to a novel stem cell-based liver therapy
GoLiver Therapeutics has been awarded €1.6m from France 2030 to progress its first biomedicine, developed from pluripotent stem cells, into the clinic for the treatment of severe liver failures.
Nantes, France, September 25th, 2024 – GoLiver Therapeutics, a start-up focused on the development of advanced therapy medicinal products and the industrial processes necessary for their manufacturing, is pleased to announce that it has won the “Innovations in Biotherapies and Bioproduction” call for proposal launched by the French government to make France a European leader in the biotherapy sector. The start-up will receive a €1.6 million investment from France 2030.